Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

Francesca Chiarini, 1 Federica Falà, 1 Pier Luigi Tazzari, 3 Francesca Ricci, 2 Annalisa Astolfi, 2 Andrea Pession, 2 Pasquale Paolo Pagliaro, 3 James A. McCubrey, 5 and Alberto M. Martelli 1, 4

1 Department of Human Anatomical Sciences and 2 Pediatric Oncology and Haematology Unit, University of Bologna, 3 Immunohaematology and Transfusion Center, Policlinico S. Orsola-Malpighi, and 4 GM Consiglio Nazionale delle Ricerche, Sezione di Bologna c/o I.O.R., Bologna, Italy; and 5 Department of Microbiology and Immunology, School of Medicine, East Carolina University, Greenville, North Carolina

Abstract
Recent investigations have documented that constitutively activated phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature of T-cell acute lymphoblastic leukemia (T-ALL), where it strongly influences growth and survival. These findings lend compelling weight for the application of PI3K/Akt/mTOR inhibitors in T-ALL. However, our knowledge of PI3K/Akt/mTOR signaling in T-ALL is limited and it is not clear whether it could be an effective target for innovative therapeutic strategies. Here, we have analyzed the therapeutic potential of the dual PI3K/mTOR inhibitor PI-103, a small synthetic molecule of the pyridofuropyrimidine class, on both T-ALL cell lines and patient samples, which displayed constitutive activation of PI3K/Akt/mTOR signaling. PI-103 inhibited the growth of T-ALL cells, including 170-kDa P-glycoprotein overexpressing cells. PI-103 cytotoxicity was independent of p53 gene status. PI-103 was more potent than inhibitors that are selective only for PI3K (Wortmannin, LY294002) or for mTOR (rapamycin). PI-103 induced G0-G1 phase cell cycle arrest and apoptosis, which was characterized by activation of caspase-3 and caspase-9. PI-103 caused Akt dephosphorylation, accompanied by dephosphorylation of the Akt downstream target, glycogen synthase kinase-3β. Also, mTOR downstream targets were dephosphorylated in response to PI-103, including p70S6 kinase, ribosomal S6 protein, and 4E-BP1. PI-103 strongly synergized with vincristine. These findings indicate that multitargeted therapy toward PI3K and mTOR alone or with existing drugs may serve as an efficient treatment toward T-ALL cells, which require up-regulation of PI3K/Akt/mTOR signaling for their survival and growth. [Cancer Res 2009;69(8):3520–8]

Introduction
Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway plays a central role in cancer biology, conferring resistance both in vivo and in vitro to therapeutic treatments of various types of malignancies that include leukemias (1–3). Upon activation, PI3K generates phosphatidylinositol 3,4,5 trisphosphate, which then activates a number of downstream targets, including Akt. A fundamental negative regulator of the PI3K/Akt pathway is the lipid phosphatase PTEN (phosphatase and tensin deleted on chromosome 10), which removes the 3-phosphate from phosphatidylinositol 3,4,5 trisphosphate, thus down-modulating PI3K/Akt signaling (2, 3). A PI3K/Akt downstream target that plays an important role in tumorigenesis and drug resistance is mammalian target of rapamycin (mTOR; ref. 4). mTOR phosphorylates p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). By doing so, mTOR increases synthesis of proteins that are important for cell cycle regulation. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder of lymphoblasts committed to the T-cell lineage (5). Over the past 20 years, survival rates of T-ALL patients have improved, due to advances in therapeutic protocols (6). Survival rates at 5 years for children and adolescents with T-ALL are 70% to 75%, whereas for adults, they are 35% to 40% (7). Nevertheless, novel therapies aimed at improperly activated signaling pathways are needed to combat induction failure, relapse rate, and the development of drug-resistance in T-ALL patients (7). Aberrant Notch-1 receptor signaling is a hallmark of T-ALL (8). Fifty-percent of T-ALL patients display Notch-1 activating mutations (7). As a consequence, the receptor is activated independently of the ligand (9). Other Notch-1 mutations impair its degradation and result in a longer receptor half-life (9, 10). When the intracellular portion of Notch-1 is released through cleavage mediated by γ-secretase (GSI), it translocates to the nucleus where it affects gene expression (11). Therefore, GSI inhibition could be exploited to abrogate aberrant Notch-1 signaling in T-ALL. However, the results of the first clinical trial testing the GSI inhibitor, MK-0752, in relapsed/refractory T-ALL patients, showed no clinical responses and a high incidence of gastrointestinal toxicity (9). Recently, it was shown that in T-ALL, activated Notch-1 leads to PI3K/Akt signaling upregulation by hairy and enhancer of split 1–mediated transcriptional repression of PTEN (12). Other reports have highlighted that PTEN posttranslational inactivation through phosphorylation and oxidation could result in PI3K/Akt/mTOR activation in T-ALL (13). These findings lend compelling weight for the application of PI3K/Akt/mTOR inhibitors in T-ALL (14). mTOR inhibitors are being evaluated for treatment of several types of tumors, including leukemias (15). Rapamycin or its analogues, used alone or in combination with traditional chemotherapeutic drugs, have shown some promising effects in preclinical models of T-ALL (e.g., ref. 14). However, mTOR inhibitors are mainly cytostatic (16) and could hyperactivate Akt due to the existence of feedback loops between mTOR, PI3K, and Akt (17). Recently, dual PI3K/mTOR inhibitors have been synthesized, including PI-103, a small molecule of the
pyrido[3,4-d]pyrimidine class (18). Because PI-103 targets class IA PI3K in addition to mTOR, it should not lead to Akt activation, which is seen when only mTOR is targeted by inhibitors (18). Moreover, PI-103 should affect mTOR signaling also when it is activated independently from PI3K/Akt, as described in some T-ALL cases (19). Here, we have analyzed the therapeutic potential of PI-103 on both T-ALL cell lines and patient samples. We have shown that this drug displays strong cytotoxic activity against T-ALL cells.

Materials and Methods

Materials. PI-103 was purchased from Alexis Biochemicals. Rapamycin, LY294002, and Wortmannin were from Sigma-Aldrich. PI100 P3IK inhibitor [compound 15e or (3-[4-(4-Morpholinyl)thieno(3,2-d)pyrimidin-2-yl]-phenol)] was from Alexis, whereas p110α (TGX-221) and p110γ (5-[2,2-Difluorobenzol(1,3)dioxol-5-ylmethylene]-thiazolidine-2,4-dione) P3IK inhibitors and Akt 1/2 inhibitor were from Calbiochem-Novabiochem. For Western blots, the following primary antibodies were from Cell Signaling Technology: β-actin, Akt, Ser 473 p-Akt (which recognizes both Akt1 and Akt2 when phosphorylated on Ser 473 and Ser 474, respectively), p70S6K, Thr 389 p-p70S6K, 4E-BP1, Thr 37/46 p-4E-BP1, glycogen synthase kinase (GSK)-3β, Ser 21/9 p-GSK-3β, S6 ribosomal protein (56RP), Ser 235/236 p-56RP, p160 γ PI3K, caspase-3, and caspase-9. Antibodies to β1010x, p110x, and p110γ P3IK were from Upstate Biotechnology/Millipore Corporation. Antibodies to Akt1 (raised in goat) and Akt2 (raised in mouse) were from Santa Cruz Biotechnology.

Antibodies to Akt1 (raised in goat) and Akt2 (raised in mouse) were from Santa Cruz Biotechnology.

PI-103–Mediated Cytotoxicity in T-ALL

Results

PI-103 has cytotoxic proapoptotic effects on T-ALL cell lines. The effect of the dual PI3K/mTOR inhibitor PI-103 on PTEN-negative T-ALL cell lines was examined first. Although Jurkat and MOLT-4 cells do not express p53, CEM cells display nonfunctional p53 (data not shown; ref. 25). Moreover, both Jurkat and MOLT-4 cells have aberrant Notch-1 signaling (26). T-ALL cell lines were treated with different concentrations of PI-103. After 24 and 48 hours, the rates of survival were measured using MTT assays. Cell lines displayed an IC50 for PI-103 ranging from 0.25 to 1.0 μmol/L at 24 hours and from 0.25 to 0.40 μmol/L at 48 hours. The vehicle alone (DMSO) did not affect cell survival (data not shown). Remarkably, also the drug-resistant CEM-R cell line, a subclone overexpressing 170-kDa P-glycoprotein, showed sensitivity to PI-103 (IC50, 0.6 μmol/L at 24 hours and 0.25 μmol/L at 48 hours; Fig. 1A). A comparison was made between PI-103 and inhibitors of either mTOR (rapamycin) or P13K (Wortmannin, LY294002). Rapamycin was less effective than PI-103 in negatively affecting cell growth of T-ALL cell lines, also when used at equimolar concentrations, (Fig. 1B). Wortmannin was much less effective than PI-103 and the same was true of LY294002, which approached PI-103 cytotoxicity only when used at 25 to 50 μmol/L (Fig. 1B).

It was next investigated whether decreased cell proliferation was related to apoptosis, using Annexin V-FITC/PI staining and flow cytometry. After 9 hours of treatment, ~45% of CEM-R cells were apoptotic with 25% in early apoptosis (Annexin V-FITC positive only) and 20% mid/late apoptosis (Annexin V-FITC/PI positive), whereas ~9% of CEM-S cells were positive for early apoptosis (Annexin V-FITC only) and another 33% were positive for both Annexin-V and PI, indicating mid/late apoptotic cells. The degree of apoptosis induced in MOLT-4 and Jurkat cells by PI-103 was similar to that detected in CEM-S cells (Supplementary Fig. S1A). Both rapamycin and LY294002 were much less effective than PI-103 in inducing apoptosis (Supplementary Fig. S1A). Given the fundamental role played by PI3K/Akt/mTOR signaling in cell proliferation, the effects of PI-103 on cell cycle progression were also investigated. Flow cytometric analysis of PI-stained T-ALL cells treated with PI-103 for 16 hours documented an increase in G0-G1 phase cells and a decrease in S and G2-M phase cells (Supplementary Fig. S1B). As rapamycin is mainly cytostatic, we reasoned that MTT assay could not be the most appropriate technique to calculate its IC50. Therefore, we also performed flow cytometric analysis of cell cycle. However, as shown in Supplementary Fig. S2, this technique also documented that the IC50 was not reached even at 3 μmol/L rapamycin for CEM-R, CEM-S, and MOLT-4 cells, whereas for Jurkat cells the decrease in cell proliferation was around 50% at 3 μmol/L.

Overall, these findings showed that PI-103 potentely reduced the growth of T-ALL cell lines and that this effect was due to both apoptosis and cell cycle arrest.

PI-103 induces caspase activation. A distinguishing feature of apoptotic cell death is the activation of a family of proteases called saponin-based reagent 2 (Beckman Coulter) as reported elsewhere (23, 24). Cells were incubated with primary antibody to Ser473 p-Akt, Thr 37/46 p-4E-BP1, or cleaved caspase-3. All the antibodies were from Cell Signaling and were conjugated to AlexaFluor 488. A rabbit IgG conjugated to AlexaFluor 488 was used as an irrelevant antibody. Cells were analyzed on an FC500 flow cytometer (Beckman Coulter). At least 10,000 events per sample were acquired.

PI-103 has cytotoxic proapoptotic effects on T-ALL cell lines. The effect of the dual PI3K/mTOR inhibitor PI-103 on PTEN-negative T-ALL cell lines was examined first. Although Jurkat and MOLT-4 cells do not express p53, CEM cells display nonfunctional p53 (data not shown; ref. 25). Moreover, both Jurkat and MOLT-4 cells have aberrant Notch-1 signaling (26). T-ALL cell lines were treated with different concentrations of PI-103. After 24 and 48 hours, the rates of survival were measured using MTT assays. Cell lines displayed an IC50 for PI-103 ranging from 0.25 to 1.0 μmol/L at 24 hours and from 0.25 to 0.40 μmol/L at 48 hours. The vehicle alone (DMSO) did not affect cell survival (data not shown). Remarkably, also the drug-resistant CEM-R cell line, a subclone overexpressing 170-kDa P-glycoprotein, showed sensitivity to PI-103 (IC50, 0.6 μmol/L at 24 hours and 0.25 μmol/L at 48 hours; Fig. 1A). A comparison was made between PI-103 and inhibitors of either mTOR (rapamycin) or P13K (Wortmannin, LY294002). Rapamycin was less effective than PI-103 in negatively affecting cell growth of T-ALL cell lines, also when used at equimolar concentrations, (Fig. 1B). Wortmannin was much less effective than PI-103 and the same was true of LY294002, which approached PI-103 cytotoxicity only when used at 25 to 50 μmol/L (Fig. 1B).

It was next investigated whether decreased cell proliferation was related to apoptosis, using Annexin V-FITC/PI staining and flow cytometry. After 9 hours of treatment, ~45% of CEM-R cells were apoptotic with 25% in early apoptosis (Annexin V-FITC positive only) and 20% mid/late apoptosis (Annexin V-FITC/PI positive), whereas ~9% of CEM-S cells were positive for early apoptosis (Annexin V-FITC only) and another 33% were positive for both Annexin-V and PI, indicating mid/late apoptotic cells. The degree of apoptosis induced in MOLT-4 and Jurkat cells by PI-103 was similar to that detected in CEM-S cells (Supplementary Fig. S1A). Both rapamycin and LY294002 were much less effective than PI-103 in inducing apoptosis (Supplementary Fig. S1A). Given the fundamental role played by PI3K/Akt/mTOR signaling in cell proliferation, the effects of PI-103 on cell cycle progression were also investigated. Flow cytometric analysis of PI-stained T-ALL cells treated with PI-103 for 16 hours documented an increase in G0-G1 phase cells and a decrease in S and G2-M phase cells (Supplementary Fig. S1B). As rapamycin is mainly cytostatic, we reasoned that MTT assay could not be the most appropriate technique to calculate its IC50. Therefore, we also performed flow cytometric analysis of cell cycle. However, as shown in Supplementary Fig. S2, this technique also documented that the IC50 was not reached even at 3 μmol/L rapamycin for CEM-R, CEM-S, and MOLT-4 cells, whereas for Jurkat cells the decrease in cell proliferation was around 50% at 3 μmol/L.

Overall, these findings showed that PI-103 potentely reduced the growth of T-ALL cell lines and that this effect was due to both apoptosis and cell cycle arrest.

PI-103 induces caspase activation. A distinguishing feature of apoptotic cell death is the activation of a family of proteases called p-Akt, p-4E-BP1, and cleaved caspase-3 levels in T-ALL patient samples. Blasts from 7 pediatric patients with T-ALL were fixed in reagent 1 of the Intraprep kit and permeabilized with heat-inactivated fetal bovine serum. Patient samples or peripheral blood lymphocytes from healthy donors were obtained with informed consent according to institutional guidelines and isolated by Ficoll-Paque (Amer sham Biosciences).

Cytofluorometric analysis of p-Akt, p-4E-BP1, and cleaved caspase-3. All the antibodies were from Cell Signaling Technologies. Cells were incubated with primary antibody to Ser473 p-Akt, Thr 37/46 p-4E-BP1, or cleaved caspase-3. All the antibodies were from Cell Signaling Technologies.
caspases, which are responsible for most of the biochemical and morphologic changes that characterize apoptosis (27). Western blotting analysis of extracts from both CEM-R and MOLT-4 cells treated with PI-103 documented that cleavage of procaspase-9 and procaspase-3 was detectable at 8 hours of treatment. In contrast, rapamycin activated caspase-3 and caspase-9 only in MOLT-4 cells, and at a later time (16 h; Fig. 2).

**PI-103 affects PI3K/Akt/mTOR signaling in T-ALL cell lines.** Western blot analysis with an antibody to Ser 473 p-Akt showed a marked decrease in this p-Akt form in response to 0.75 μmol/L PI-103 already after 8 hours of treatment (Fig. 3A). Rapamycin (0.1 μmol/L) treatment transiently activated Ser 473 p-Akt at 8 hours, in agreement with others (28). The p-Akt levels then decreased, but at 48 hours, they increased again. Total Akt levels were unaffected by either PI-103 or rapamycin. Akt inhibition by PI-103 had functional consequences because the well-established Akt downstream target, GSK3-β, showed a decreased phosphorylation level, whereas the expression of total GSK3-β was unaffected. p-GSK-3β behavior in response to rapamycin was similar to p-Akt in that it increased at 8 hours, then decreased and increased again at 48 hours. mTOR downstream substrates (p70S6K, 4E-BP1, and S6RP) were efficiently dephosphorylated by both PI-103 and rapamycin, with the exception of 4E-BP1 that was resistant to rapamycin (Fig. 3A). A dose-dependent investigation carried on CEM-R cells showed that PI-103 induced Akt dephosphorylation already at 125 nmol/L, whereas 4E-BP1 dephosphorylation was detectable at 250 nmol/L (Fig. 3B).

**Characterization of PI3K/Akt signaling in T-ALL cells.** No information is available regarding the class I PI3K catalytic subunits and Akt isoforms that are active in PTEN-negative T-ALL cell lines. This issue is relevant to cancer therapy, as Akt isoform-specific inhibitors are actively sought (29). Moreover, inhibitors selective for class I PI3K catalytic subunits are being tested in clinical trials (30). Immunoprecipitation experiments were performed on extracts from T-ALL cells using antibodies specific for either Akt1 or Akt2. The immunoprecipitates were blotted to nitrocellulose membranes that were then probed with the antibody used for the immunoprecipitation, or an antibody that recognizes both Akt1 or Akt2 when phosphorylated on Ser 473 and Ser 474, respectively. We found that T-ALL cell lines expressed both Akt1 and Akt2 that were phosphorylated (Fig. 4A). As a control, the blots with the Akt1 immunoprecipitates were probed with the antibody to Akt2, and vice versa. The antibody to Akt2 picked up some bands in the Akt1 blots; however, the molecular weight of these
bands did not correspond to Akt1 molecular weight (60 kDa). In contrast, the antibody to Akt1 did not pick up any bands in the Akt2 blots (Fig. 4A).

T-ALL cell lines expressed p110α, p110β, p110γ, and p110δ PI3K, as shown by Western blot analysis (Fig. 4B). We next examined the effects of p110 PI3K isoform selective inhibitors to establish which isoforms were involved in T-ALL cell survival (Fig. 4B). We used compound 15e, which inhibits p110α PI3K with an IC50 of 0.58 μmol/L (31), TGX-221, which displays an IC50 of around 40 nmol/L for p110δ PI3K (32), and 5-[2,2-Difluoro-benzo(1,3)-dioxol-5-ylmethylene]-thiazolidine-2,4-dione, which has an IC50 of ~250 nmol/L against p110γ PI3K (33). MTT assays were performed after 24 hours of treatment. A dose-dependent decrease in cell survival was obtained with the p110α PI3K selective inhibitor. In contrast, inhibitors of β and γ p110 PI3K had either much lower (β) or no (γ) effects (Fig. 4B). No effects were observed with a p110δ PI3K-selective inhibitor (data not shown; ref. 32). Consistently, inhibition of Ser 473 p-Akt phosphorylation was maximally observed with the α inhibitor, and to a much lower extent with β inhibitor, whereas the γ inhibitor actually increased Akt phosphorylation when used at 2 μmol/L (Fig. 4C). The p110δ PI3K inhibitor was ineffective in dephosphorylating Akt (data not shown). Immunoprecipitation experiments documented that the p110α PI3K inhibitor dephosphorylated both Akt1 and Akt2 in Jurkat cells. Also, PI-103 dephosphorylated both Akt isoforms (Fig. 4D). However, when the p110α PI3K selective inhibitor was...
combined with rapamycin, the growth inhibition effect was not as strong as with PI-103. An allosteric Akt 1/2 inhibitor (34) was less effective than PI-103, when used at equimolar concentrations (Supplementary Fig. S3A–B). Also, this inhibitor was much less cytotoxic than PI-103 when used against CEM-R cells. Overall, these experiments showed that T-ALL cell lines display both p-Akt1 and p-Akt2 expression and that p110α PI3K is the most important isoform for their growth.

PI-103 synergizes with vincristine. It was investigated whether PI-103 could synergize with vincristine, a drug commonly used for treating T-ALL patients (35). Previous reports have indicated that mTOR activation specifically confers resistance to chemotherapeutic drugs that target the microtubules, including vincristine (36). T-ALL cell lines were incubated for 24 hours with vincristine alone, PI-103 alone, or the drugs together at a fixed ratio (PI-103/ vincristine, 25:1). MTT assays were then performed. The combined treatment was much more cytotoxic than either of the two drugs alone (Fig. 5A). Analysis of the combination index documented the existence of a strong synergism (combination index, <0.3) at PI-103 concentrations that were well below the IC50 (Fig. 5B).

T-ALL blasts are sensitive to PI-103. To better assess the effectiveness of PI-103 as a potential therapeutic agent in T-ALL, we examined pediatric T-ALL patient samples isolated from bone marrow or peripheral blood, for the levels of Ser 473 p-Akt and Thr 37/46 p-4E-BP1, as well as for their sensitivity to PI-103, using flow cytometry and MTT assays. The clinical features of T-ALL patients are presented in Supplementary Table S1. All patient samples (7 of 7) had higher levels of p-Akt and p-4E-BP1 than those detected in peripheral blood lymphocytes from healthy donors (data not shown; Fig. 6A). Flow cytometric analysis documented a decrease in the levels of Ser 473 p-Akt in samples treated with PI-103 (Fig. 6B). The same technique also showed increased levels
of cleaved caspase-3 after treatment with PI-103, which were higher than in samples exposed to rapamycin (Fig. 6C). To determine the susceptibility of T-ALL lymphoblasts to inhibition of PI3K/Akt/mTOR signaling, the samples were treated with increasing concentrations of PI-103 for 96 hours, and cell survival was analyzed by MTT assays. A strong reduction of cell viability at 96 hours was detected. The IC50 for patient samples ranged between 0.18 and 0.63 μmol/L PI-103. Overall, these findings showed that PI-103 has a potent cytotoxic activity and activated caspase-3 also in primary cells from T-ALL patients with up-regulated PI3K/Akt/mTOR signaling.

Discussion

The PI3K/Akt/mTOR pathway is a recently identified potential target for therapeutic intervention in T-ALL. Here, we have shown that PI-103 has a strong cytotoxic activity against T-ALL cell lines and lymphoblasts derived from T-ALL patients. Thus far, the antiproliferative effects of PI-103 have been mainly documented in glioblastomas (18) and in acute myeloid leukemia (AML) cells (37, 38), PI-103 cytotoxicity in T-ALL cell lines was independent of the p53 gene status. It should be emphasized that p53 mutations are associated with a much worse prognosis in T-ALL patients (39). Our findings are different to those reported for AML cell lines, where the modest cytotoxic effect of PI-103 could be enhanced by the murine double minute-2 inhibitor, Nutlin-3, in a wild-type p53-dependent fashion (38). In this respect, our results are in agreement with those reported for glioblastoma cell lines, where PI-103 was cytotoxic independently of the p53 gene status (18).

Moreover, PI-103 was effective also against a CEM cell subclone, CEM-R, which overexpresses high levels of 170-kDa P-glycoprotein, one of the main determinants of drug resistance. This observation is relevant, as 170 kDa P-glycoprotein is detected in ~24% of T-ALL patients and negatively correlates with the achievement of a complete remission (40, 41). In T-ALL cell lines, PI-103 induced both G0-G1 phase cell cycle arrest and apoptosis, which was characterized by activation of caspase-9 and caspase-3. In contrast, in AML cell lines, PI-103 was mainly cytostatic and did not induce apoptosis or only had a modest apoptogenic activity (37, 38). PI-103 was capable of dephosphorylating Akt and its downstream target, GSK-3β, as well as mTOR downstream targets. PI-103 strongly synergized with vincristine, a drug used in treating T-ALL patients. Remarkably, PI-103 displayed cytotoxic activity against lymphoblasts from patients with pediatric T-ALL characterized by enhanced levels of p-Akt and p-4E-BP1. Also, in patient samples, PI-103 dephosphorylated Akt and activated caspase-3.

In our hands, PI-103 was more effective than rapamycin alone in negatively affecting growth of T-ALL cells, even when used on an equimolar basis. PI-103 was also more effective than Wortmannin, an irreversible PI3K inhibitor. LY294002, a reversible PI3K inhibitor, displayed a potency that approached that of PI-103 only when used at extremely high concentrations.

Because rapamycin and its analogues only target mTORC1 and not mTORC2 (which is responsible for Ser 473 p-Akt phosphorylation; ref. 17), it has been shown that the use of these inhibitors could indeed result in Akt hyperactivation (28). Consistently, we have observed that rapamycin treatment of T-ALL cell lines resulted in Akt hyperactivation at 8 and 48 hours. Also the Akt substrate GSK-3β displayed hyperphosphorylation at the same times, implying an activation of Akt by rapamycin. In contrast, PI-103, which has been documented to inhibit both mTORC1

Figure 5. A PI-103 and vincristine combination is synergistic in MOLT-4, JURKAT, and CEM-S cell lines. A, cells were cultured in presence of vincristine (VCR) and PI-103 alone, or in combination, at a fixed ratio (1:25). The combined treatment was highly effective in inducing cytoxicity, as shown by MTT assays at 24 h. Points, mean of at least three different experiments; bars, SD. B, the combination index value for each data point was calculated with the appropriate software for dose effect analysis (CalcuSyn).
and mTORC2 activity (18), did not hyperactivate Akt in T-ALL cells, even at later incubation times, and this might be related to mTORC2 inhibition. A previous report highlighted that in Jurkat cells, prolonged treatment with rapamycin inhibited mTORC2 at 24 hours (42). However, that study did not examine later times. At present, we do not know if the hyperphosphorylation of Akt we observed after 48 hours of treatment with rapamycin was due to a low stability of the drug in vitro or to other reason(s). Interestingly, PI-103, but not rapamycin, dephosphorylated 4E-BP1. This might be due to the fact that, in T-ALL cells, 4E-BP1 is downstream of PIM kinases and not of mTORC1. This would not be unprecedented, as it has been recently shown to occur in AML cells (43). Therefore, we could hypothesize that PI-103, by blocking PI3K/Akt, would result also in PIM kinase downregulation, as PIM kinases have been reported to be downstream of PI3K/Akt (44). Lack of 4E-BP1 dephosphorylation by rapamycin could also explain why the drug is less efficacious than PI-103 against T-ALL cell lines.

We also have shown for the first time that T-ALL cell lines express Akt1 and Akt2. Both of these isoforms were constitutively

Figure 6. PI-103 is cytotoxic to primary lymphoblasts from pediatric patients (Pt) with T-ALL, displaying constitutive phosphorylation of Akt and 4E-BP1 and inducing caspase-3 activation. A, samples from T-ALL patients were analyzed by flow cytometry for the levels of Ser 473 p-Akt and Thr 37/46 p-4E-BP1. Four representative patients are shown. Black histograms, negative control (irrelevant antibody); gray histograms, cells positive for the specific antibody. B, patient samples were analyzed by flow cytometry for the levels of Ser 473 p-Akt before and after treatment with PI-103 (0.5 μmol/L for 72 h). Black histograms, negative control (irrelevant antibody); gray histograms, cells positive for the specific antibody; CTRL, control cells. C, patient samples were treated with 0.1 μmol/L rapamycin or 0.5 μmol/L PI-103 or DMSO for 72 h, then analyzed by flow cytometry for cleaved caspase-3. Black histograms, DMSO-treated samples; gray histograms, drug-treated samples. D, MTT assay of T-ALL blasts treated with PI-103 for 96 h. Points, mean of at least two different experiments; bars, SD; *, statistically significant difference (P < 0.001) with respect to untreated cells. Four representative patients are shown.
phosphorylated, and PI-103 down-regulated their phosphorylation levels. Another new finding from our study is that in T-ALL cell lines, p110α PI3K, seems to be the most important isoform for cell growth and Akt1/Akt2 phosphorylation. PI-103 was originally described as a compound specifically targeting p110α PI3K (18), although subsequent investigations have highlighted that it also inhibited other class IA PI3Ks (37). However, a combination of rapamycin plus the p110α PI3K inhibitor, 15e, was less effective than PI-103. Also, an Akt1/Akt2 allostERIC inhibitor was less effective than PI-103.

In conclusion, we have provided evidence that PI-103, either alone or in combination with vincristine, is a highly effective drug against T-ALL cells, also derived from patients. It displayed cytoxic activity against cells with activating Notch-1 mutations, such as Jurkat and MOLT-4, which are resistant to GSI (26). PI-103 has proven efficacy also in vivo against models of human tumors xenografted in mice, where it displayed low toxicity and was well-tolerated (18, 28). Interestingly, in a mouse model of tumors xenografted in mice, where it displayed low toxicity and it also inhibited other class IA PI3Ks (37). However, a combination of rapamycin plus the p110α PI3K inhibitor, 15e, was less effective than PI-103. An Akt1/Akt2 allostERIC inhibitor was less effective than PI-103.

PI-103 did not induce apoptosis in normal human CD34+ cells and had moderate effects on their clonogenicity and proliferation (37). This could indicate that dual targeting of PI3K/mTOR signaling would not detrimentally affect normal hematopoiesis in humans. PI-103 did not enter clinical trials mainly because of its rapid drug elimination (47). Nevertheless, we feel that our findings strongly support the hypothesis that longitudinal inhibition at two nodes of the PI3K/Akt/mTOR pathway in T-ALL cells could ensue in more effective results than the use of a single inhibitor targeting either PI3K or mTOR.

 Recently, a new orally available dual PI3K/mTOR inhibitor, NVP-BEZ235, has entered phase I clinical trials (48). It will be interesting to test if NVP-BEZ235 is as effective as PI-103 against T-ALL cells. These investigations could pave the way for using dual PI3K/mTOR inhibitors to improve the therapeutic outcome of T-ALL patients displaying activation of PI3K/Akt/mTOR signaling.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 12/22/08; revised 2/16/09; accepted 2/16/09; published OnlineFirst 4/7/09.

Grant support: Fondazione Cassa Di Risparmio Di Bologna and Progetti Strategici Università di Bologna EF2006 (A.M. Martelli) and NIH (RO1CA098195; J.A. McIver). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

9. Palomero T, Chiarini F, DelSole M, Mongiorgi S, et al. The novel Akt1/Akt2 allosteric inhibitor was less effective than PI-103. Also, an Akt1/Akt2 allostERIC inhibitor was less effective than PI-103.
23. Demarest RM, Ratti F, Capobianco AJ. Reciprocal regulation of Notch and mTOR as an


# Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

Francesca Chiarini, Federica Falà, Pier Luigi Tazzari, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-08-4884</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2009/04/06/0008-5472.CAN-08-4884.DC1">http://cancerres.aacrjournals.org/content/suppl/2009/04/06/0008-5472.CAN-08-4884.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 48 articles, 14 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/69/8/3520.full.html#ref-list-1">http://cancerres.aacrjournals.org/content/69/8/3520.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 14 HighWire-hosted articles. Access the articles at: /content/69/8/3520.full.html#related-urls</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>